Luo et al. [13] followed 69 patients with lung cancer infected with COVID-19, including 41 patients who had previously received PD-1 blockade and 28 patients who had not received yet, and found no difference in COVID-19 severity (hospitalization, intensive care unit (ICU)/intubation/transition to do not intubation, and mortality) between these two groups. This evidence concerns the gene PDCD1 and lung cancer.